IHC should be performed as primary testing to evaluate HER2 protein expression status, as it is widely available in most pathology laboratories, is relatively inexpensive, and is the only recommended test available at the present time to detect HER2-low protein expression (tumor with IHC 1+ or IHC 2+ with non-amplified gene status). The gene discussed is ERBB2; the disease is neoplasm.